AKT1 and neoplasm: Collectively, these results indicate that osimertinib plus aspirin significantly slows tumor growth, prolongs survival, and may overcome osimertinib resistance in vivo by inhibiting Akt/FoxO3a signaling phosphorylation and increasing Bim expression.